Last Week Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Ratings

May 17, 2018 - By Lindsey Price

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Corporate Logo

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Ratings Coverage

A total of 2 analysts rate Collegium Pharmaceutical (NASDAQ:COLL) as follows: 2 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:COLL) has 6 ratings reports on May 17, 2018 according to StockzIntelligence. On Thursday, December 7 the stock has “Buy” rating by Piper Jaffray. On Thursday, December 14 the stock has “Buy” rating by Piper Jaffray. On Tuesday, January 23 the stock has “Buy” rating by Piper Jaffray. On Monday, February 12 the stock has “Buy” rating by Piper Jaffray. The company rating was maintained by Jefferies on Sunday, February 11. In Wednesday, November 29 report Piper Jaffray maintained it with “Buy” rating and $19.0 target. Listed here are Collegium Pharmaceutical, Inc. (NASDAQ:COLL) PTs and latest ratings.

12/02/2018 Broker: Piper Jaffray Rating: Buy New Target: $33.0 Maintain
11/02/2018 Broker: Jefferies Rating: Buy New Target: $32.0 Maintain
23/01/2018 Broker: Piper Jaffray Rating: Buy New Target: $33.0 Maintain
14/12/2017 Broker: Piper Jaffray Rating: Buy New Target: $23.0 Maintain
07/12/2017 Broker: Piper Jaffray Rating: Buy New Target: $24.0 Maintain
29/11/2017 Broker: Piper Jaffray Rating: Buy New Target: $19.0 Maintain

COLL is touching $25.1 during the last trading session, after increased 2.20%.Currently Collegium Pharmaceutical, Inc. is uptrending after 133.98% change in last May 17, 2017. COLL has 186,789 shares volume. COLL outperformed by 122.43% the S&P500.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases.The firm is worth $829.40 million. It offers Xtampza, an oral formulation of oxycodone, for the management of pain.Last it reported negative earnings. The firm also develops Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older.

For more Collegium Pharmaceutical, Inc. (NASDAQ:COLL) news published briefly go to: Globenewswire.com, Nasdaq.com, Seekingalpha.com, Globenewswire.com or Seekingalpha.com. The titles are as follows: “Collegium Reports First Quarter Financial Results and Provides Corporate Update” published on May 09, 2018, “Why Depomed Inc.’s Shares Soared 23.2% Higher” on May 10, 2018, “FDA OKs first non-opioid treatment for opioid withdrawal” with a publish date: May 16, 2018, “Collegium to Present at the Deutsche Bank Health Care Conference” and the last “Collegium Pharmaceutical’s (COLL) CEO Michael Heffernan on Q1 2018 Results – Earnings Call Transcript” with publication date: May 10, 2018.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.